Drug-Coated Balloons for the Treatment of Coronary Artery Disease: A Review
Authors' conclusion
Although commercially available in numerous countries now for more than a decade, DCB only recently obtained US Food and Drug Administration approval for the treatment of coronary ISR.
Study context
- Population
- Patients with coronary in-stent restenosis (ISR) or de novo CAD
- Comparison
- Drug-coated balloon (DCB) angioplasty vs drug-eluting stent (DES) implantation for percutaneous coronary intervention (PCI)
Main finding
As reported in the abstract
Advantages and indications of DCB angioplasty (narrative review)
- DCBs offer advantages over DES, including preservation of vessel anatomy and function and positive vessel remodeling
- Appealing for ISR, small-vessel disease, long lesions, simplification of bifurcation procedures, and diffuse distal disease after chronic total occlusion recanalization
- Patients with high bleeding risk, DM and ACS might also benefit
Original publication
Drug-Coated Balloons for the Treatment of Coronary Artery Disease: A Review. JAMA Cardiol. Published 1 February 2025. doi:10.
Summarised from the published abstract; every number is checked against it